Re-shoring life sciences for a sustainable future
6 November 2025
The pandemic, geopolitical tensions and the climate emergency have revealed the vulnerabilities of Europe’s life sciences industry. Relocating pharmaceutical and medtech production is no longer a choice but a strategic necessity to safeguard sovereignty, strengthen competitiveness and ensure long-term sustainability.
In partnership with HealthTech for Care, Forvis Mazars has carried out an in-depth study drawing on more than 20 interviews with leaders from pharmaceutical companies, medtechs, biotechs, CDMOs, investors and institutional experts. The research examines the practical conditions required to build a resilient European value chain.
Key insights
- Nearly 80% of pharmaceutical active ingredients used in Europe are imported from Asia
- More than 60% of European biotechs struggle to finance their transition to industrialisation
- On average, 18 months are needed to obtain CE certification for a medical device
The findings reveal a sharp divide between political ambition and industrial reality. Complex regulation, limited access to industrial land and fragile economic models are slowing progress. At the same time, Europe’s advantages such as low-carbon energy, centres of excellence and high ESG standards remain underused.
Innovation is flourishing, yet without adequate funding, breakthroughs in areas such as AI, continuous bioproduction and cell therapy risk moving abroad.
Relocation is therefore both an industrial challenge and a public health imperative. By securing supply chains, reducing emissions and building resilience, Europe can guarantee patients faster, safer and more reliable access to life-saving treatments.
Want to know more?
